ENIGMATRIX

Enigmatrix is based on a fully human monoclonal antibody inhibitor of the FBG region of tenascin C (TnC) that blocks a fundamental mechanism of multiple cancers.

This mechanism is especially strong in hard-to-treat cancers, such as pancreatic cancer, glioblastoma and mesothelioma.

In a spontaneous breast cancer model in vivo, Enigmatrix showed:

  • Reduced primary cancer cell growth,

  • Significantly reduce metastasis,

  • A reduction in the levels of pro-cancer M2 macrophages,

  • Upregulation of some immune responses, and

  • That its effects were complementary to other cancer therapies.

More scientific data is being generated to support the hypothesis that this technology weakens the cancer, stops it spreading and inhibits cancers control over its microenvironment.

We are working to optimise delivery of Enigmatrix for each cancer we work on to ensure it reaches the place where is it needed the most.

Role of Tenascin C

Tenascin C is a multi-domain protein physiologically expressed and involved in wound healing processes and is found pathologically in situations of chronic inflammation, such as arthritis.

However, over the last 40 years there have been numerous scientific publications showing that this protein is also expressed in a large number of cancers. A clear picture is emerging that the higher the levels of tenascin C the more aggressive, resistant and difficult to treat the cancer.

Tenascin C can be secreted by cancer cells, by stromal cells or by both. The best prognosis for cancer patients is where neither of these cell types produce tenascin C, with the worst outcome for those where both cell types produce it.

Tenascin C expression is often focused at the margins of the tumor where it is expanding. It also forms tracks within the tumor which have been hypothesized to be escape routes for metastatic tumor cells.

Tenascin C is known to promote metastasis, and may be involved in preparing tissue sites to receive the metastases.

Tenascin C has also been shown to promote the M2 phenotype of macrophages, which are pro-cancer.